A Rheumatologist Managing Patients with Rheumatoid Arthritis: An Artisan But Also An Artist!

Dougados, Maxime

doi:10.3899/jrheum.121086

Cited by 2 publications

(3 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our center, as well as in the literature, AAV usually occurred after RA in patients with both RA and AAV [10][11][12][13][14][15][16][17][18][19][20][21][22][23][24]. This may partially be ascribed to the successful inhibition of RA occurrence by intense immunosuppression in the treatment of AAV.…”

Section: Discussionmentioning

confidence: 78%

“…RA is largely an inflammatory disease limited to joints, whereas AAV is a systemic autoimmune disease usually with multi-organ destructive processes and devastating outcomes. It has been reported that AAV can coexist with RA [3,[8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24]. This coexistence may not be entirely coincidental, as evidenced by facts such as ANCA positivity in 20% of RA patients [25], a positive association between ANCA titer and rapid joint destruction in early RA [26], the presence of myeloperoxidase-ANCA in synovial fluid of RA patients [27], and AAV sharing susceptibility loci with RA [28,29].…”

Section: Discussionmentioning

confidence: 99%

“…Patients with suspected drug-induced AAV were excluded. We pooled these cases with those from our center [3,[8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24]…”

Section: Patients With Both Aav and Ra From Our Center And The Litera...mentioning

confidence: 99%

See 2 more Smart Citations

Anti-neutrophil cytoplasmic antibody associated vasculitis in patients with rheumatoid arthritis

et al. 2022

BMC Nephrol

View full text Add to dashboard Cite

Background Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) may coexist with rheumatoid arthritis (RA). However, it is unclear whether the manifestations of AAV with and without coexisting RA are similar. This observational study aimed to investigate the clinicopathological manifestations of AAV with coexisting RA and to explore potential predictors for identifying AAV superimposed on RA. Methods Patients with both AAV and RA were identified by searching our hospital database and the literature. Data including age, sex, clinical manifestation, laboratory tests, renal pathology, and therapeutic regimens were retrieved. To assess the difference in clinical features and renal pathology between AAV patients with and without RA, we conducted 1:4 matched case-control studies. Results A total of 47 patients were identified, 15 from our hospital and 32 from the literature, and 33 (70.2%) were women. AAV was diagnosed later than RA in 83.0% of the patients and manifested as microscopic polyangiitis (MPA) in 78.7% of the patients. The kidney was the most frequently involved extra-articular organ (74.5%), followed by the lung (51.1%), and skin (8.5%). Patients with both AAV and RA were more likely to be asymptomatic (26.7% vs 3.3%, p = 0.013) than those with isolated AAV. However, they did not differ in other clinicopathological features. In RA patients, those with ANCA associated glomerulonephritis, were more likely to have decreased renal function at renal biopsy as opposed to those with primary glomerulonephritis. Conclusions AAV can coexist with RA. In this coexistence, AAV usually develops after RA, is more likely to be asymptomatic, and manifests predominately as MPA with renal involvement. Thus, we should remain vigilant to superimposed AAV on RA.

show abstract

Section: Discussionmentioning

confidence: 78%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Anti-neutrophil cytoplasmic antibody associated vasculitis in patients with rheumatoid arthritis

et al. 2022

BMC Nephrol

View full text Add to dashboard Cite

show abstract

Treat to Target in Psoriatic Arthritis—Evidence, Target, Research Agenda

Coates

Helliwell

2015

Curr Rheumatol Rep

View full text Add to dashboard Cite

This article summarises the evidence on treating to target (T2T) in psoriatic arthritis (PsA). The evidence from the recent European League Against Rheumatism (EULAR) literature search in SpA is reviewed. This article found no studies in SpA in 2011 which compared a T2T approach against standard care in a randomised controlled trial (RCT). One of the issues raised in PsA is what target to use. The minimal disease activity (MDA) criteria were developed specifically for PsA and have been validated in observational and interventional cohorts. These have now been utilised in the Tight Control of PsA (TICOPA) study comparing T2T to standard care in early PsA providing the first evidence that T2T in PsA can improve outcomes. To translate this into clinical practice in PsA, patient education and feasibility are key. Future research must address the optimal therapies to be used within a T2T framework which will need to take subtype of PsA into account.

show abstract

A Rheumatologist Managing Patients with Rheumatoid Arthritis: An Artisan But Also An Artist!

Cited by 2 publications

References 16 publications

Anti-neutrophil cytoplasmic antibody associated vasculitis in patients with rheumatoid arthritis

Anti-neutrophil cytoplasmic antibody associated vasculitis in patients with rheumatoid arthritis

Treat to Target in Psoriatic Arthritis—Evidence, Target, Research Agenda

Contact Info

Product

Resources

About